Cover Image
市場調查報告書

5'-核苷酸酵素:開發中產品分析

5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 365780
出版日期 內容資訊 英文 36 Pages
訂單完成後即時交付
價格
Back to Top
5'-核苷酸酵素:開發中產品分析 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 36 Pages
簡介

本報告提供以5'-核苷酸酵素為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,再加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

5'-核苷酸酵素 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Corvus Pharmaceuticals, Inc.
  • Innate Pharma S.A.
  • MedImmune, LLC
  • Vitae Pharmaceuticals, Inc.

藥物簡介

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0244TDB

Summary

Global Markets Direct's, '5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) - Pipeline Review, H1 2016', provides in depth analysis on 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) targeted pipeline therapeutics.

The report provides comprehensive information on the 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5)
  • The report reviews 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) Overview
  • Therapeutics Development
    • 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) - Products under Development by Stage of Development
    • 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) - Products under Development by Therapy Area
    • 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) - Products under Development by Indication
  • 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) - Pipeline Products Glance
    • Early Stage Products
  • 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) - Products under Development by Companies
  • 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) - Products under Development by Universities/Institutes
  • 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) - Companies Involved in Therapeutics Development
    • Corvus Pharmaceuticals, Inc.
    • Innate Pharma S.A.
    • MedImmune, LLC
    • Vitae Pharmaceuticals, Inc.
  • 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) - Drug Profiles
    • Antibody to Inhibit CD73 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • durvalumab + MEDI-9447 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-9447 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit CD73 for Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit CD73 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit CD73 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CD73 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CD73 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) - Featured News & Press Releases
    • Apr 18, 2016: Innate Pharma presents new CD73 checkpoint inhibitor program
    • Feb 24, 2014: CD73 Research Could Lead to Cancer Drug
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Corvus Pharmaceuticals, Inc., H1 2016
  • Pipeline by Innate Pharma S.A., H1 2016
  • Pipeline by MedImmune, LLC, H1 2016
  • Pipeline by Vitae Pharmaceuticals, Inc., H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top